文献速递主动脉外科

既往心血管手术后再次全主动脉弓置换的早期与晚期结局:10年经验

Early and Late Outcomes of Redo Procedure for Total Arch Replacement After Previous Cardiovascular Surgery: 10-Year Experience.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

该回顾性研究纳入2013至2023年117例既往心血管手术后行全主动脉弓置换的患者,分析手术指征、围术期资料及远期结局。院内死亡率为6.8%,主要不良事件发生率为13.7%;1年、3年、5年总体生存率分别为90.1%、86.9%、80.0%,5年再干预累积发生率为17.20%。

要点

  • 再次全主动脉弓置换院内死亡率为6.8%,主要不良事件发生率为13.7%。
  • 5年总体生存率为80.0%,5年再干预累积发生率为17.20%。
  • 双侧脑灌注者术中鼻咽温与膀胱温更低,血小板输注量更少,神经功能缺损无显著差异。

核心结论

  • 再次全主动脉弓置换技术挑战大,但通过个体化手术规划和终末器官保护可获得可接受的早期和晚期结果。

研究设计与样本

  • 回顾性分析2013年1月至2023年11月单中心117例既往心血管手术后行全主动脉弓置换的患者。
  • 收集手术指征、围术期资料、术后并发症及远期结局进行分析。

主要发现

  • 患者平均年龄46.8±13.0岁,女性32例(27.4%)。
  • 再次手术指征包括主动脉弓动脉瘤11例(9.4%)、慢性夹层动脉瘤样扩张35例(29.9%)、计划分期手术3例(2.6%)、主动脉炎2例(1.7%)及医源性原因16例(13.7%)。
  • 院内死亡率为6.8%,主要不良事件发生率为13.7%。
  • 双侧脑灌注者术中鼻咽温[23.4°C(20.4°C-25.0°C)vs 26.8°C(25.0°C-27.5°C),P < .001]和膀胱温(25.5±3.2°C vs 28.8±1.8°C,P < .001)显著更低,血小板输注量更少[中位数1.0(1.0-2.0)vs 1.00(1.0-1.0),P = .003],术后神经功能缺损无显著差异。
  • 1年、3年、5年总体生存率分别为90.1%(95%CI:84.2%-96.5%)、86.9%(95%CI:79.8%-94.6%)、80.0%(95%CI:70.5%-90.8%);随访期间14例接受主动脉相关再干预,5年再干预累积发生率为17.20%(95%CI:7.22%-26.11%)。

临床怎么用

  • 对于既往心血管手术后需全主动脉弓置换的患者,个体化手术规划和终末器官保护策略有助于获得可接受的早远期结果。
  • 双侧脑灌注可能与更低的术中温度和更少的血小板输注相关,且不增加术后神经功能缺损。

局限性

  • 本研究为单中心回顾性分析,样本量有限,结果可能受选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the early and late outcomes of the redo procedure for total arch replacement following previous cardiovascular surgery. METHODS: Between January 2013 and November 2023, 117 patients underwent total aortic arch replacement after previous cardiovascular surgery in our centre. Surgical indication, perioperative data, postoperative complications, and late outcomes were retrospectively analysed. RESULTS: The mean age of patients was 46.8 ± 13.0 years, and 32 were female (27.4%). Indications for redo procedure included aortic arch aneurysm (11, 9.4%), aneurysmal expansion of a chronic dissection (35, 29.9%), staged surgery in plan (3, 2.6%), aortitis (2, 1.7%), and iatrogenic reasons (16, 13.7%). In-hospital mortality was 6.8% with 13.7% major adverse events. Patients who received bilateral cerebral perfusion had significantly higher intraoperative temperatures [nasopharyngeal: 23.4°C (20.4°C-25.0°C) vs 26.8°C (25.0°C-27.5°C), P < .001; bladder: 25.5 ± 3.2°C vs 28.8 ± 1.8°C, P < .001] and required fewer platelet transfusions [median units: 1.0 (1.0-2.0) vs 1.00 (1.0-1.0), P = .003], with no significant differences in postoperative neurological deficits. Overall survival of the patients was 90.1% [95% confidence interval (CI): 84.2%-96.5%], 86.9% (95% CI: 79.8%-94.6%), and 80.0% (95% CI: 70.5%-90.8%) at 1, 3, and 5 years, respectively. During follow-up, 14 patients received aortic-related reintervention. The cumulative incidence of reintervention was 17.20% (95% CI: 7.22%-26.11%) at 5 years. CONCLUSIONS: Although redo total arch replacement is technically challenging, acceptable early and late results can be obtained through tailored surgical planning and end-organ protection.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Zhao R, Wang W, Liu Y, et al. Early and Late Outcomes of Redo Procedure for Total Arch Replacement After Previous Cardiovascular Surgery: 10-Year Experience. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40719775. doi:10.1093/icvts/ivaf179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。